Table of Contents
ISRN Endocrinology
Volume 2011, Article ID 287052, 4 pages
Research Article

Decrease in TSH Receptor Autoantibodies during Antithyroid Treatment: Relationship with a Long Noncoding Heg RNA and Cdk1 mRNA in Mononuclear Cells

Endocrine Research Laboratory, Medical Department O, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark

Received 23 April 2011; Accepted 17 May 2011

Academic Editor: S. Tezelman

Copyright © 2011 Niels Juel Christensen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. J. Christensen, G. Habekost, and P. Bratholm, “A RNA transcript (Heg) in mononuclear cells is negatively correlated with CD14 mRNA and TSH receptor autoantibodies,” Clinical and Experimental Immunology, vol. 154, no. 2, pp. 209–215, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. Buza, P. Benjamin, J. Zhu et al., “CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands,” Veterinary Immunology and Immunopathology, vol. 126, no. 3-4, pp. 273–282, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. P. Cui, Q. Lin, F. Ding et al., “A comparison between ribo-minus RNA-sequencing and polyA-selected RNA-sequencing,” Genomics, vol. 96, no. 5, pp. 259–265, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. R. Volpé, “Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review,” Thyroid, vol. 4, no. 2, pp. 217–223, 1994. View at Google Scholar · View at Scopus
  5. A. Lucas, I. Salinas, F. Rius et al., “Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?” The Journal of Clinical Endocrinology and Metabolism, vol. 82, pp. 2410–2413, 1997. View at Google Scholar
  6. J. Orgiazzi, “Anti-TSH receptor antibodies in clinical practice,” Endocrinology and Metabolism Clinics of North America, vol. 29, no. 2, pp. 339–355, 2000. View at Google Scholar · View at Scopus
  7. D. A. Chistiakov, “Thyroid-stimulating hormone receptor and its role in Graves' disease,” Molecular Genetics and Metabolism, vol. 80, no. 4, pp. 377–388, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. T. F. Davies, X. Yin, and R. Latif, “The genetics of the thyroid stimulating hormone receptor: history and relevance,” Thyroid, vol. 20, no. 7, pp. 727–736, 2010. View at Google Scholar · View at Scopus
  9. D. Santamaria, C. Barriere, A. Cerqueira et al., “Cdk1 is sufficient to drive the mammalian cell cycle,” Nature, vol. 448, pp. 811–816, 2007. View at Google Scholar
  10. T. Engstrom, P. Bratholm, H. Vilhardt, and N. J. Christensen, “Beta2-adrenoceptor desensitization in non-pregnant estrogen-primed rat myometrium involves modulation of oxytocin receptor gene expression,” Journal of Molecular Endocrinology, vol. 20, pp. 261–270, 1998. View at Google Scholar